Covid infection can cause months-long brain injury

London: Markers of brain injury continue to be present in the blood many months after Covid-19 infection, despite inflammation blood tests being normal, finds a study.

The study, published in the journal Nature Communications, identified ongoing brain injury markers in those who developed neurological complications during Covid-19.

During the Covid-19 pandemic it became apparent that neurological complications were occurring in a significant proportion of hospitalised patients and even in those with mild Covid-19 infection. While some neurological 'symptoms' were often mild {headache and muscle aches (myalgia)}, it became clear that more significant and potentially life-changing new neurological 'complications' were occurring, including encephalitis (brain inflammation), seizures, and stroke, said researchers from the University of Liverpool in the UK.

The team analysed samples from over 800 patients hospitalised with Covid-19 from across England and Wales, half of whom with new neurological conditions. The researchers measured brain injury markers, serum inflammatory proteins (cytokines), antibodies, and brain (neuroglial) injury proteins.

The analysis of these, shows that during the acute phase (when symptoms are developing quickly) there is production of key inflammatory proteins and brain injury markers but surprisingly on-going robust biomarker evidence of brain (neuroglial) injury in Covid even months after discharge from hospital.

Crucially, this was more prominent in patients with neurological dysfunction in the acute phase of the illness, and continued in the recovery phase in patients who had suffered acute neurological complications. The inflammatory markers are associated with abnormal immune responses in the acute phase of the disease, and the researchers suggest that these may represent targets for therapy for Covid-19 and other infections which cause acute brain dysfunction.

"Our study shows that markers of brain injury are present in the blood months after Covid-19, and particularly in those who have had a Covid-19-induced brain complication (e.g. inflammation, or stroke), despite resolution of the inflammatory response in the blood. This suggests the possibility of ongoing inflammation and injury inside the brain itself which may not be detected by blood tests for inflammation," said Professor Benedict Michael, principal investigator and director of the University of Liverpool, UK.

"By bringing together immunology, neurology and infection research, we were able to reveal a number of biomarkers that were associated with the neurological complications of Covid-19. This work may help set the stage for elucidating the possible underlying mechanisms of these complications," added Professor Leonie Taams, from King's College London.

52% jump in Covid

cases globally

The global number of new Covid-19 cases has increased by 52 per cent during the last one month, the World Health Organization (WHO) said on Saturday. In the latest epidemiological update on Friday, the UN health body reported over 850,000 new cases worldwide in the 28-day period from November 20 to December 17.

The number of new deaths decreased by 8 per cent as compared to the previous 28-day period, with over 3,000 new fatalities reported. As of

December 17, over 772 million confirmed cases and nearly seven million deaths have been reported globally. During the period from November 13 to December 10, over 118,000 new Covid hospitalisations and over 1,600 new intensive care unit (ICU) admissions have been recorded with an overall increase of 23 per cent and 51 per cent respectively amongst the countries reporting consistently within the current and past reporting periods.

The WHO last week designated JN.1, a sub-lineage of BA.2.86 Omicron variant, as a separate variant of interest (VOI) apart from its parent lineage BA.2.86 due to its rapid increase in prevalence in recent weeks. However, EG.5 remains to be the most reported VOI globally.

At the global level, during the past 28 days, a total of 118,958 new hospitalisations and 1,610 new intensive care unit (ICU) admissions were reported from 58 and 36 countries, respectively.

The South-East Asia Region reported over 9,200 new cases, a 388 per cent increase as compared to the previous 28-day period. The highest numbers of new cases were reported from Indonesia (3,725), followed by India (3,241) and Thailand (2,120).

The WHO emphasised that current vaccines continue to provide protection against severe disease and death from the JN.1 variant and other circulating variants of SARS-CoV-2. The organisation is closely monitoring the evidence and will update the risk evaluation of JN.1 as needed.